Pegcrisantaspase

N/A

Report date: 2024/02/05 13:26:07

Base Information

Drug NamePegcrisantaspase
Drug Alias NamePolyethylene-glycol-Erwinia-chrisanthemi-L-asparaginasePegylated erwinia chrysanthemi l-asparaginasePegylated dickeya chrysanthemi l-asparaginasemPEG-R-CrisantaspasePEGylated-Erwinia-chrysanthemi-L-asparaginase +[9] 
ClassificationBiologics > Protein drugs > Enzyme > Recombinant enzymeBiologics > Protein drugs > Recombinant protein > Recombinant enzyme
Mechanisms of ActionAspartate-ammonia ligase inhibitorsAmidohydrolases stimulants
TargetsAspartate-ammonia ligaseAmidohydrolases
Therapy Area/IndicationsHematologic NeoplasmsLeukemia, Myeloid, AcuteLeukemia, Myelogenous, Chronic +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesFrance
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesAlizé Pharma Iii Sas
China Registration ClassN/A

Develop Information

Active CompaniesEusa PharmaUniversity Of Maryland, Baltimore
Inactive CompaniesThe University Of Texas MD Anderson Cancer CenterJazz Pharmaceuticals Plc
Active IndicationsLeukemia, Myeloid, Acute
Inactive IndicationsHematologic NeoplasmsLeukemia, Myelogenous, ChronicPrecursor Cell Lymphoblastic Leukemia-Lymphoma +[5] 

Other Information

ATC CodeN/A
Related LinksDrugBank